SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Zimmer ER) "

Sökning: WFRF:(Zimmer ER)

  • Resultat 1-10 av 15
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Carter, SF, et al. (författare)
  • Astrocyte Biomarkers in Alzheimer's Disease
  • 2019
  • Ingår i: Trends in molecular medicine. - : Elsevier BV. - 1471-499X .- 1471-4914. ; 25:2, s. 77-95
  • Tidskriftsartikel (refereegranskat)
  •  
5.
  •  
6.
  •  
7.
  • Leuzy, A, et al. (författare)
  • Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?
  • 2014
  • Ingår i: TRANSLATIONAL NEUROSCIENCE. - : Walter de Gruyter GmbH. - 2081-3856 .- 2081-6936. ; 5:1, s. 51-56
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Recent advances along clinical and neuropathological lines, as well as in our ability to detect the deposition of β-amyloid (Aβ) in vivo using positron emission tomography (PET), have helped redefine Alzheimer’s disease (AD) as a dynamic clinicobiological entity. On the basis of these advances, AD is now conceptualized as a continuum comprising asymptomatic, minimally symptomatic, and dementia phases, with detection of brain Aβ — in particular, via PET amyloid imaging — central to the diagnostic process. In this respect, [18F]florbetapir (Amyvid™) and [18F]flutemetamol (Vizamyl™) have recently received approval for clinical use from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with additional radiofluorinated tracers for detection of Aβ in phase III trials. Recent initiatives such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) suggest that Aβ production, oligomerization and aggregation begins many years, possibly decades, before detectable cognitive impairment, with Aβ shown to associate with cognitive decline and conversion to dementia. While personalized medicine has now emerged as a prospect for the field, the recent decision by the Centers for Medicare & Medicaid Services (CMS) — who declined to cover the cost of amyloid PET imaging citing insufficient evidence to support its clinical utility — highlights that such a move may be premature.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 15

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy